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Abstract
Kaposi’s sarcoma-associated herpesvirus (KSHV) is one of the few oncogenic human
viruses known to date. Its large genome encodes more than 85 proteins and includes both
unique viral proteins as well as proteins conserved amongst herpesviruses. KSHV ORF20
is a member of the herpesviral core UL24 family, but the function of ORF20 and its role in
the viral life cycle is not well understood. ORF20 encodes three largely uncharacterized iso-
forms, which we found were localized predominantly in the nuclei and nucleoli. Quantitative
affinity purification coupled to mass spectrometry (q-AP-MS) identified numerous specific
interacting partners of ORF20, including ribosomal proteins and the interferon-stimulated
gene product (ISG) oligoadenylate synthetase-like protein (OASL). Both endogenous and
transiently transfected OASL co-immunoprecipitated with ORF20, and this interaction was
conserved among all ORF20 isoforms and multiple ORF20 homologs of the UL24 family in
other herpesviruses. Characterization of OASL interacting partners by q-AP-MS identified a
very similar interactome to that of ORF20. Both ORF20 and OASL copurified with 40S and
60S ribosomal subunits, and when they were co-expressed, they associated with poly-
somes. Although ORF20 did not have a global effect on translation, ORF20 enhanced RIG-I
induced expression of endogenous OASL in an IRF3-dependent but IFNAR-independent
manner. OASL has been characterized as an ISG with antiviral activity against some vi-
ruses, but its role for gammaherpesviruses was unknown. We show that OASL and ORF20
mRNA expression were induced early after reactivation of latently infected HuARLT-
rKSHV.219 cells. Intriguingly, we found that OASL enhanced infection of KSHV. During
infection with a KSHV ORF20stop mutant, however, OASL-dependent enhancement of
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infectivity was lost. Our data have characterized the interaction of ORF20 with OASL and
suggest ORF20 usurps the function of OASL to benefit KSHV infection.
Author summary
The herpesviruses are a family of large double-stranded DNA viruses that cause a variety
of illnesses from chicken pox to cancer. Kaposi’s sarcoma-associated herpesvirus (KSHV)
is a cancer-causing herpesvirus and can lead to development of Kaposi’s sarcoma, a major
form of cancer in HIV-positive patients. As for all herpesviruses, infection with KSHV is
lifelong. Exactly how KSHV initiates and maintains its infection is still not well under-
stood, but it must manipulate the host cell to establish favorable conditions. Likewise, the
host has developed a complicated system to fight off invaders, which includes the produc-
tion of interferon-stimulated gene products. We have now found that KSHV exploits one
such host cell protein, the oligoadenylate synthetase-like protein (OASL). Rather than
OASL acting as an antiviral protein as it does during many other viral infections, KSHV
appears to have found a way to utilize OASL for its own benefit. The KSHV protein
ORF20 interacts with OASL, they co-localize in nucleoli, and both ORF20 and OASL asso-
ciate and purify with components of the cellular translational machinery. This may help
viral infection by selectively controlling protein production.
Introduction
The oncogenic human herpesvirus 8, also known as Kaposi’s sarcoma-associated herpesvirus
(KSHV), belongs to the Gammaherpesvirinae subfamily of the Herpesviridae [1]. KSHV is the
etiological agent of multiple malignancies, including Kaposi’s sarcoma, which is a common
form of cancer in HIV-infected individuals [2], and primary effusion lymphoma, an aggressive
non-Hodgkin’s lymphoma [3]. After successful primary infection of the host, KSHV, like all
herpesviruses, can undergo lytic replication or establish latency in infected cells [4]. While the
mechanisms leading to transformation and oncogenesis are still not completely understood,
the current view is that both lytic replication and latency are important for KS tumor develop-
ment [4].
KSHV has a large dsDNA genome with more than 85 open reading frames (ORFs) encod-
ing proteins at least 100 amino acids (aa) in length. In addition, it utilizes mechanisms like
splicing, mRNA editing, and alternative start codons to further maximize genomic capacity
[5]. The poorly characterized ORF20 is an example of this additional complexity. Wildtype
ORF20 (ORF20WT) encodes 3 colinear isoforms: the 320 amino acid long full length isoform
ORF20FL, the 297 amino acid isoform ORF20A, and the 257 amino acid isoform ORF20B.
The sequences for ORF20FL (AAC57101.1) and ORF20B (ABD28871.1), both of which start
with a methionine, were submitted to Genbank as part of the genomic annotations for the
minor and predominant (M and P) strains of KSHV, respectively, despite the presence of the
sequences encoding ORF20FL and ORF20B in both genomes. ORF20A was identified much
more recently and its translation utilizes a noncanonical leucine via a CTG start codon [5].
ORF20 is a member of the herpesviral core UL24 gene family and is conserved in the
Alpha-, Beta-, and Gammaherpesvirinae. Transiently expressed HSV-1 UL24, KSHV
ORF20WT, HCMV UL76, and MHV68 ORF20 have been reported to affect the mitotic cdc2/
cyclinB complex, thereby inducing cell cycle arrest and apoptosis [6, 7]. However, studies with
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MHV68 WT and ORF20 mutant viruses found no effect on the cell cycle [8]. Multiple UL24
family members, including HSV-1 UL24, HCMV UL76, and KSHV ORF20WT, localize to the
nucleoli of transfected cells [9, 10]. KSHV ORF20 mRNA is expressed late upon de novo infec-
tion of primary human umbilical vein endothelial cells. ORF20 mRNA is also detected upon
reactivation of a latently infected body cavity based lymphoma cell line (BCBL-1) [11]. To
date, the function of ORF20 is not well understood, and furthermore, the biological relevance
of the different ORF20 isoforms is unclear.
Interferon-stimulated gene (ISG) transcription, including that of 2’-5’-oligoadenylate syn-
thetase-like protein (OASL), is activated upon pattern recognition receptor and type I inter-
feron (IFN) receptor signaling [12–15]. ISGs have evolved as a host defense mechanism and
fall into three different categories: broadly acting antiviral effectors, ISGs with targeted antivi-
ral specificity, and proviral ISGs that enhance the replication of certain viruses [15]. OASL
expression is induced by viral infection. For example, both Sendai virus and influenza virus
infection upregulate OASL in an early IFN regulatory factor 3 (IRF3)-dependent manner [13].
In a screen of almost 400 ISGs that characterized their antiviral activity against six different
viruses, OASL was identified as an ISG with targeted antiviral specificity [15].
Lentiviral expression of OASL inhibited replication of hepatitis C virus, but not replication
of human immunodeficiency virus type-1, yellow fever virus, West Nile virus, chikungunya virus,
or Venezuelan equine encephalitis virus [15]. In a subsequent study that also primarily focused on
RNA viruses, OASL inhibited poliovirus, equine arterivirus, and Newcastle disease virus, mildly
inhibited influenza A virus and measles virus, but did not inhibit coxsackie B virus, Sindbis virus
AR86, Sindbis virus Girdwood, o’nyong-nyong virus, human parainfluenza virus type 3, respira-
tory syncytial virus, bunyamwera virus, nor did it inhibit the DNA virus vaccinia [16]. The role of
OASL for HSV-1 is more controversial; in one study, OASL expression was shown to have no
effect on HSV-1 replication [17], and in another, OASL inhibited HSV-1 [18].
OASL is a member of the oligoadenylate synthetase protein family that includes the promi-
nent enzymes cyclic GMP-AMP (cGAMP) synthase (cGAS) and 2’-5’-oligoadenylate synthase
1 (OAS1), as well as OAS2 and OAS3. The OAS enzymes and cGAS are activated by cytosolic
double-stranded nucleic acids and produce 2’-5’-linked second messenger molecules [19].
While OASL shares a highly conserved N-terminal OAS-like domain with the OAS enzymes,
it lacks enzymatic activity and has a unique C-terminus composed of two ubiquitin-like
domains (UBL) [20]. Additionally, OASL has a double-stranded RNA (dsRNA) binding
groove and the OAS-like domain binds dsRNA [21].
OASL is conserved between mice and humans; murine OASL1 (mOASL1) is the most simi-
lar to human OASL (hOASL), and like hOASL, mOASL1 lacks enzymatic activity and has a
UBL [22]. mOASL2 is more distantly related to hOASL; it possesses enzymatic activity, unlike
hOASL, but like OASL has a UBL [22]. mOASL1 has been shown to inhibit IRF7 translation
by binding to the 5’ untranslated region (UTR) of IRF7, and compared to wildtype mice,
mOASL1 knockout mice are more resistant to HSV-1 and EMCV infection, likely due to
increased interferon production [23]. However, unlike mOASL, hOASL does not seem to bind
to the IRF7 UTR [18]. A yeast two-hybrid screen that utilized a human leukocyte cDNA library
identified the transcriptional repressor methyl CpG binding protein 1 (MBD1) as an interact-
ing partner of OASL [24]. Another study found that hOASL enhanced RIG-I signaling, and
furthermore showed that OASL co-immunoprecipitated with RIG-I [18]. To date, however,
the function of OASL is not completely understood and no viral binding partners have previ-
ously been identified. Furthermore, its role during gammaherpesvirus infections is unknown.
We have now characterized all three isoforms of KSHV ORF20 and show that they localize
to the nuclei and nucleoli of transiently transfected or transduced cells, including HeLa, 293T,
primary HFF, HuARLT2, and HuARLT2-rKSHV.219. In an unbiased quantitative affinity
OASL interacts with KSHV ORF20
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006937 March 2, 2018 3 / 37
purification coupled to mass spectrometry (q-AP-MS) approach, we identify OASL as an inter-
action partner of ORF20. We show that the interaction with OASL is conserved among ORF20
isoforms and UL24 family members present in other herpesviruses. We analyze the OASL
interactome by q-AP-MS and find that OASL and ORF20 share numerous ribosomal interac-
tion partners. Furthermore, both proteins copurify with 40S and 60S ribosomal subunits.
Moreover, when expressed together they associate with polysomes, but do not have a global
effect on translation. Interestingly, ORF20 upregulates OASL mRNA expression downstream
of RIG-I in an IRF3-dependent manner, but independently of IFNAR signaling. During reacti-
vation of latently infected HuARLT2-rKSHV.219, both OASL and ORF20 mRNA levels are
upregulated early. Lastly, OASL enhances KSHV infection in an ORF20-dependent manner,
suggesting that KSHV has commandeered this ISG to benefit KSHV infection.
Results
KSHV ORF20 encodes three isoforms with predominantly nuclear and
nucleolar localization
KSHV ORF20 is a member of the conserved UL24 family but to date it has not been extensively
characterized. The ORF20 genomic locus encoded on the minus strand of the genome is 660
nucleotides in length and although the 5’ and 3’ untranslated regions are not known [5], it is
anticipated that one mRNA is transcribed (Fig 1A). Next generation ribosomal footprinting
data identified initiating ribosomes at three positions, giving rise to three colinear isoforms of
ORF20: full-length ORF20 (ORF20FL) as well as two shorter isoforms, ORF20A, which starts at
an alternative leucine start codon at amino acid 24 of ORF20FL, and ORF20B, which starts at
an internal methionine at amino acid 64 of ORF20FL (Fig 1A) [5]. The anticipated sizes of all
three protein isoforms are 35, 32, and 28 kDa, respectively (Fig 1A). A plasmid construct encod-
ing genomic ORF20WT [10], equipped with a C-terminal myc epitope tag, can potentially
Fig 1. KSHV ORF20 encodes three isoforms. (A) KSHV ORF20WT, a member of the UL24 family, can potentially express three isoforms: ORF20FL, starting at
methionine 1 (M1) (aa 1–320), ORF20A, starting at leucine 24 (L24) (aa 1–297), and ORF20B, starting at M64 (aa 1–257). (B) Plasmid constructs express the three
isoforms singly or in combination with each other as indicated. For analysis of ORF20A, either the genomic L24 start codon (ORF20WT and ORF20FLgA) or
genomic L24 with an upstream methionine, indicated with M (ORF20A, ORF20AB) was used.  indicates genomic ORF20A leucine start codon; ORF20A starting
with leucine was not detectable by immunoblotting. (C) Expression vectors encoding ORF20WT, individual ORF20 isoforms, or ORF20 isoforms in combination
with each other were transfected into 293T cells. Lysates were prepared 24 h later, separated by Bis-Tris PAGE, and anti-myc and anti-tubulin immunoblotting was
performed. Empty vector (EV) was included as a control. The immunoblot is representative of four independent experiments.
https://doi.org/10.1371/journal.ppat.1006937.g001
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express ORF20FL, ORF20A, and ORF20B (Fig 1B), but we only observed two distinct bands
upon immunoblotting cell lysates with an anti-myc antibody (Fig 1C). To identify the isoforms
responsible for these two bands, we cloned all isoforms singly and in combination (Fig 1B) and
analyzed their expression by immunoblotting (Fig 1C). We found that the two bands observed
upon expression of ORF20WT correspond to ORF20FL and ORF20B (Fig 1C). We could not
detect expression of ORF20A from ORF20WT or ORF20FLgA plasmid constructs that contain
the genomic leucine start codon, but could drive expression of ORF20A by addition of an N-ter-
minal methionine in ORF20A and ORF20AB constructs (Fig 1B and 1C).
A previous study has shown that KSHV ORF20WT localizes to the nucleus [10]. However,
the localization of all individual ORF20 isoforms has not yet been studied. We determined the
subcellular localization of ORF20WT as well as the individual ORF20 isoforms ORF20FL,
ORF20A, and ORF20B in HeLa cells by immunofluorescence (IF) and confocal microscopy.
First, we analyzed the localization of ORF20 isoforms in whole cell IF. All isoforms localized
predominantly to the nuclei and nucleoli, where they co-localized with Hoechst and the nucle-
olar protein fibrillarin, but in some cells ORF20 forms could also be detected in the cytoplasm
(Fig 2A). To enhance visualization of the nucleoli, we performed nuclear IF. For this, we
extracted the cytoplasm by incubation with 1% NP-40 extraction buffer prior to fixation. By
labeling the nucleolar marker fibrillarin, we confirmed that all KSHV ORF20 isoforms local-
ized to the nucleoli (Fig 2B).
ORF20 interacts with ribosomal proteins and the oligoadenylate
synthetase-like protein OASL
To better understand the function of ORF20, we utilized q-AP-MS [25, 26] to identify cellular
binding partners of ORF20. HeLa S3 cells were metabolically labeled with stable heavy or light
isotopes of arginine and lysine, then transfected with myc-tagged ORF20WT or LacZ as a
Fig 2. KSHV ORF20 isoforms localize predominantly to the nuclei and nucleoli. (A-B) HeLa cells were transfected with the indicated plasmid and seeded onto
coverslips. 48 h post transfection, (A) coverslips were fixed directly in 4% paraformaldehyde in PBS (PFA) for whole cell immunofluorescence. (B) For nuclear
immunofluorescence, coverslips were incubated in cold 1% NP-40 extraction buffer for 5 min to remove the cytoplasm before PFA fixation. (A-B) All samples were
then processed for anti-myc (green) and anti-fibrillarin (red) immunofluorescence. Nuclei were counterstained with Hoechst (blue). Images are representative of three
independent experiments. Scale bar = 10 μm.
https://doi.org/10.1371/journal.ppat.1006937.g002
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control. In the forward experiment, heavy labeled cells were transfected with ORF20-myc,
and light labeled cells with LacZ-myc (Fig 3A). In the crossover experiment, the labels were
exchanged. Lysates were subjected to anti-myc immunoprecipitation, then combined and sub-
jected to LC/MS-MS before peptide analysis (Fig 3A). In the forward experiment, specific inter-
action partners of ORF20 were more abundant in the heavy form than in the light form (Fig
3A), while in the crossover experiment the label switch resulted in an inverted abundance of the
same protein. In contrast, nonspecific binding partners were equally abundant in the forward
and crossover experiment. Proteins identified in both the forward and crossover experiments
were analyzed for relative ratios and graphed. Interacting partners of LacZ are displayed in the
upper left quadrant, and nonspecific interactions or contaminants are located around the origin
(Fig 3B). We identified multiple specific interacting partners of ORF20 (Fig 3B, Table 1, and S1
Dataset), which cluster in the lower right quadrant of the graph (Fig 3B). These interacting part-
ners included numerous 40S and 60S ribosomal proteins, ribosome-binding protein 1, and
OASL, an interferon-stimulated gene product (ISG) (Table 1, S1 Dataset, S1 Supporting Infor-
mation). The 40S and 60S ribosomal subunits, which contain many individual proteins as well
as the 5.8S, 18S, and 28S ribosomal RNAs (rRNAs), form the mature 80S eukaryotic ribosome.
Multiple 80S ribosomes associate to form actively translating ribosomes or polysomes [27, 28].
We next wanted to confirm the interaction of ORF20 with endogenous OASL in wildtype
293T and HeLa S3 cells, using 293T OASL-/- cells as a specificity control (Fig 3C). As OASL is
an ISG, we transfected cells with a constitutively active mutant of the pattern recognition
receptor RIG-I, RIG-I N, to enhance expression of endogenous OASL. Endogenous OASL was
specifically expressed in RIG-I N transfected 293T cells, but not in the absence of RIG-I N
transfection or in 293T OASL-/- cells. In HeLa S3 cells, OASL was detected both in the presence
and absence of RIG-I N. We immunoprecipitated ORF20WT with an anti-myc antibody, then
analyzed immunoprecipitates for the presence of endogenous OASL by anti-OASL immuno-
blotting. OASL co-immunoprecipitated with ORF20WT from both 293T and HeLa S3 cells
co-transfected with RIG-I N, but not from 293T OASL-/- cells, as expected. OASL also co-
immunoprecipitated with ORF20WT from HeLa S3 cells in the absence of RIG-I N, validating
our q-AP-MS results (Fig 3C, Table 1).
As detection of endogenous OASL was challenging, we used co-transfections for further
interaction studies. To determine whether OASL interacted with all ORF20 isoforms, we co-
transfected 293T cells with V5-tagged OASL and various ORF20-myc isoform constructs or
LacZ-myc as a control. All proteins were appropriately expressed in the input lysates (Fig 3D).
We then performed an anti-myc immunoprecipitation and immunoblotted first against
V5-OASL, then verified successful immunoprecipitation of the various myc constructs (Fig
3D). We found that OASL co-immunoprecipitated with all ORF20 isoforms (FL, A, and B)
individually as well as with ORF20WT, but not with the LacZ control.
We then analyzed the subcellular localization of OASL and ORF20 by immunofluorescence.
We tested several antibodies for detection of endogenous OASL and could detect endogenous
protein by immunoblotting but not by immunofluorescence. Furthermore, there are no com-
mercial antibodies available against ORF20. Thus, to analyze localization, we transfected HeLa
S3 cells with either myc-tagged ORF20WT or V5-tagged OASL, or co-transfected them with
both plasmids. When expressed alone, ORF20WT was located predominantly in the nuclei
and nucleoli (Fig 3E). When OASL was expressed alone, it was located in the cytoplasm as well
as in the nucleoli (Fig 3E). When ORF20WT and OASL were co-expressed, their subcellular
localization was unaltered (Fig 3F). ORF20WT and OASL co-localized in the nucleoli but not
elsewhere in the cells (Fig 3F).
Next, we wanted to verify the subcellular localization of OASL and ORF20 in additional cell
types. First, we utilized HuARLT2-rKSHV.219 cells, a conditionally immortalized human
OASL interacts with KSHV ORF20
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Fig 3. Quantitative affinity purification coupled to mass spectrometry identifies OASL as an ORF20 interaction partner. (A) Scheme of the quantitative affinity
purification coupled to mass spectrometry (q-AP-MS) workflow used to identify cellular interaction partners of ORF20. In the forward experiment, HeLa S3 cells were
OASL interacts with KSHV ORF20
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endothelial cell line latently infected with recombinant KSHV rKSHV.219 [29–32]. In cells in-
fected with rKSHV.219, latently infected cells express GFP from the cellular EF-1α promoter
and upon reactivation RFP from the KSHV lytic gene PAN promoter. We transduced HuARLT2-
rKSHV.219 cells with lentiviruses encoding OASL-V5, ORF20WT-myc, ORF20FL-myc, or
ORF20B myc, then analyzed the localization in latently infected cells (Fig 4A). We found that the
localization was similar to that observed in HeLa cells; OASL was present in the cytoplasm and
nucleoli, and ORF20 forms were present in the nuclei and nucleoli (Fig 4A). To determine
whether the localization remained the same in reactivated cells, we reactivated transduced
HuARLT2-rKSHV.219 cells with sodium butyrate and a baculovirus carrying the RTA gene (Fig
4B). As in latently infected cells, in reactivated cells, OASL was present in the cytoplasm and
nucleoli, and ORF20 forms were identified in the nuclei and nucleoli (Fig 4B). We then analyzed
the subcellular localization of OASL and ORF20 forms in transiently transduced primary human
foreskin fibroblasts (S1A Fig) and conditionally immortalized HuARLT2 endothelial cells (S1B
Fig). The subcellular localization was similar to that observed in other cell types; OASL was
detected in the cytoplasm and nucleoli, and ORF20 forms in the nuclei and nucleoli.
Next, to determine whether the localization of ORF20 was dependent upon OASL expres-
sion, we transfected 293T or 293T OASL-/- cells with ORF20WT and analyzed the localization
by immunofluorescence. In both cell types, ORF20WT was detected in the nuclei and nucleoli
(S1C Fig). In parallel, we co-transfected 293T cells with ORF20WT and RIG-I N to induce
expression of endogenous OASL. Due to lack of specific antibodies for IF of endogenous
OASL, we verified nuclear translocation of endogenous IRF3 as a marker for OASL expression.
In ORF20WT expressing cells with nuclear translocation of IRF3, ORF20WT localized to the
nuclei and nucleoli (S1D Fig), similar to what we saw in HeLa cells, where endogenous OASL
was detected even in the absence of RIG-I N (Fig 3C).
In summary, ORF20 forms were consistently detected in the nuclei and nucleoli in primary
and immortalized cells and the subcellular localization of ORF20 was independent of OASL
expression. OASL was observed in the cytoplasm and nucleoli in a variety of cell types, and its
localization was independent of ORF20 expression, and ORF20 and OASL co-localized in the
nucleoli of transiently transfected cells.
As ORF20 and OASL co-localized in the nucleoli, we wanted to verify whether their interac-
tion detected by IP was specific or only due to their subcellular co-localization. To do so, we
cloned an ORF20WT-myc-GFP fusion and compared it to GFP-NS1A, in which GFP is fused
to amino acids 203–237 of influenza A/Udorn/72 NS1, conferring nucleolar localization of
GFP [33]. As a positive control, we utilized GFP-tagged RIG-I, which localizes to the cyto-
plasm, as RIG-I has previously been shown to interact with OASL under mild lysis conditions
labeled with heavy or light amino acids, then transfected with ORF20WT-myc or LacZ-myc, respectively. In the crossover experiment, ORF20WT-myc was labeled with
light amino acids and LacZ-myc with heavy amino acids. Lysates were immunoprecipitated with anti-myc magnetic beads, combined for affinity purification,
processed, and analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). ORF20 interaction partners were identified based on the increased
abundance of heavy labeled proteins compared to light labeled proteins. In the parallel crossover experiment, specific interaction partners were identified based on
increased abundance of light labeled proteins. Proteins with a 1:1 ratio of light and heavy amino acids are non-specific binding partners or contaminants. (B)
Quantitative proteomics results displayed graphically. The abundances of proteins identified in the forward and crossover experiments are graphed, with ORF20
interacting partners located in the lower right quadrant. Each point represents one protein. 40S and 60S ribosomal proteins are shown in blue and OASL is indicated in
red. (C) 293T, 293T OASL-/-, and HeLa S3 cells were transfected with ORF20WT-myc (+) or empty vector (-) and/or RIG-I N (+) or empty vector (-). An anti-myc
immunoprecipitation of NP-40 lysates was performed and input lysates and immunoprecipitates were immunoblotted with anti-OASL and anti-myc antibodies. :
Nonspecific background band. Immunoblots are representative of two independent experiments. (D) 293T cells were transfected with myc-tagged ORF20 isoforms,
LacZ-myc, OASL-V5, and/or EV as indicated. An anti-myc immunoprecipitation of RIPA lysates was performed and input lysates and immunoprecipitates were
immunoblotted with anti-V5 and anti-myc antibodies. Data are representative of three independent experiments. (E) HeLa S3 cells were transfected individually with
ORF20WT-myc or OASL-V5, then labeled with antibodies against myc or V5 as appropriate (green) and fibrillarin (red). (F) HeLa S3 cells were co-transfected with
ORF20WT-myc and OASL-V5, and then labeled with anti-V5 (green) and anti-myc (red) antibodies. Nuclei were counterstained with Hoechst (blue). Images are
representative of three independent experiments. Scale bar = 10 μm (E) and 20 μm (F).
https://doi.org/10.1371/journal.ppat.1006937.g003
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Table 1. ORF20 interacting partners identified by q-AP-MS analysis.
Protein Log2 forward Log2 crossover
60S ribosomal protein L36 2,510 -2,515
40S ribosomal protein S12 2,452 -3,281
60S ribosomal protein L10a 2,396 -2,876
Ribosome-binding protein 1 2,391 -2,467
60S ribosomal protein L15 2,272 -2,858
40S ribosomal protein S24 2,270 -2,461
60S ribosomal protein L24 2,200 -3,036
40S ribosomal protein S6 2,178 -3,063
60S acidic ribosomal protein P1 2,173 -2,173
60S ribosomal protein L7a 2,126 -2,422
60S ribosomal protein L4 2,111 -2,867
60S acidic ribosomal protein P0 2,049 -2,598
60S ribosomal protein L34 2,044 -2,889
60S ribosomal protein L8 2,027 -2,385
60S ribosomal protein L27 2,009 -2,400
60S ribosomal protein L6 2,002 -2,516
60S ribosomal protein L18 1,926 -2,353
60S ribosomal protein L30 1,913 -4,404
60S acidic ribosomal protein P2 1,860 -2,224
60S ribosomal protein L35a 1,851 -2,386
60S ribosomal protein L3 1,831 -2,463
2’-5’-oligoadenylate synthase-like protein (OASL) 1,774 -2,035
40S ribosomal protein S26 1,731 -2,700
60S ribosomal protein L7 1,712 -2,114
60S ribosomal protein L12 1,625 -2,055
60S ribosomal protein L23 1,542 -2,238
60S ribosomal protein L10 1,530 -2,498
40S ribosomal protein S2 1,404 -1,914
40S ribosomal protein S23 1,383 -1,631
60S ribosomal protein L19 1,293 -1,886
BAG family molecular chaperone regulator 2 1,284 -0,940
60S ribosomal protein L14 1,254 -2,225
28S ribosomal protein S28 1,165 -1,810
60S ribosomal protein L13 1,157 -1,756
Heterogeneous nuclear ribonucleoprotein F 1,150 -1,401
Protein LTV1 homolog 1,150 -1,512
U4/U6 small nuclear ribonucleoprotein Prp3 1,034 -0,998
60S ribosomal protein L29 1,005 -1,531
40S ribosomal protein S14 0,898 -1,993
40S ribosomal protein S3a 0,981 -1,722
40S ribosomal protein S8 0,990 -1,678
40S ribosomal protein S4, X isoform 0,713 -1,617
60s ribosomal protein L27a 0,784 -1,513
Apoptosis-inducing factor 1, mitochondrial 0,878 -1,498
60S ribosomal protein L17 0,714 -1,432
U4/U6 small nuclear ribonucleoprotein Prp31 0,776 -1,222
(Continued)
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[18]. We co-transfected OASL-V5 with two independent ORF20WT-myc-GFP clones, RIG-
I-GFP, or GFP-NS1A, as well as all singly-transfected controls, and performed an anti-V5 IP
(S2A Fig). We found that ORF20-GFP co-immunoprecipitated with OASL-V5, but GFP-
NS1A did not. RIG-I-GFP also weakly co-immunoprecipitated with OASL-V5. Next, we per-
formed an anti-GFP IP on similar samples and found that OASL-V5 strongly co-immuno-
precipitated with ORF20-myc-GFP, but not with GFP-NS1A (S2B Fig). Under our stringent
lysis conditions, OASL-V5 did not co-immunoprecipitate with RIG-I-GFP (S2B Fig). These
data confirm the interaction of ORF20 with OASL and verify that the detected interaction is
not solely due to nucleolar co-localization.
The interaction with OASL is conserved among UL24 family members
We next wanted to determine if the interaction with OASL was specific for KSHV ORF20 or if
it was conserved among UL24 family members present in the Alpha-, Beta-, and Gammaher-
pesvirinae. We compared the amino acid sequences of the UL24 family members HSV-1
UL24, HCMV UL76, MCMV M76, KSHV ORF20FL, KSHV ORF20A, KSHV ORF20B, and
MHV68 ORF20, and found that all KSHV ORF20 homologs aligned to each other and all
forms of ORF20 (S3 Fig). We cloned myc-tagged constructs utilizing the genomic nucleotide
sequence of several KSHV ORF20 homologs: HSV-1 UL24, HCMV UL76, and MCMV M76.
As MHV68 ORF20 was poorly expressed, we codon-optimized its sequence and added a 3x
myc tag. First, we analyzed the subcellular localization of all homologs in transiently trans-
fected HeLa cells. Similarly to ORF20, all UL24 family members were located in the nuclei and
nucleoli (Fig 5A). We verified expression of all homologs by immunoblotting, and found that
UL24, M76, and ORF20B were of similar sizes, while UL76 and MHV68 ORF20 were more
similar to the size of ORF20WT (Fig 5B and 5C). While codon-optimized MHV68 ORF20
expression was low compared to KSHV ORF20, it was expressed and detection of MHV68
ORF20 was improved by anti-myc immunoprecipitation prior to immunoblotting (Fig 5C).
To determine whether OASL interacted with UL24 family members, we co-transfected
293T cells with V5-tagged OASL and myc-tagged KSHV ORF20FL, MCMV M76, HCMV
UL76, or HSV-1 UL24, or LacZ-myc as a control. OASL co-immunoprecipitated strongly with
KSHV ORF20FL and MCMV M76. HCMV UL76 and HSV-1 UL24 also immunoprecipitated
OASL, but much more weakly than KSHV ORF20 (Fig 5D). OASL-V5 did not co-immu-
noprecipitate with the negative control LacZ (Fig 5D). Our results show that the interaction
with OASL is conserved among ORF20 isoforms and UL24 homologs.
The interaction of ORF20 with OASL is independent of RNA binding by
OASL
We next analyzed the interaction of ORF20 with a variety of V5-tagged OASL mutants to
determine if specific OASL domains or functions are required for the interaction to occur. The
mutants included ΔUBL, lacking the ubiquitin-like domain of OASL; P-loop mutants V67G
and N72K with reduced nucleic acid binding; three RNA binding mutants, R45E/K66E/
Table 1. (Continued)
Protein Log2 forward Log2 crossover
Pre-mRNA-processing factor 6 0,776 -1,051
Highly confident interaction partners were based on log2 fold change values with an absolute value1 in one
experiment and 0.7 in the other experiment. The complete list can be found in S1 Dataset.
https://doi.org/10.1371/journal.ppat.1006937.t001
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Fig 4. The subcellular localization of OASL-V5 and ORF20-myc isoforms is unaltered in latent and reactivated
HuARLT2-rKSHV.219 cells. HuARLT2-rKSHV.219 cells were transiently transduced with lentiviruses encoding the
indicated construct. 4 days post transduction, cells were seeded onto glass coverslips. The following day, cells were
untreated (A, latent infection) or reactivated with sodium butyrate and RTA-expressing baculovirus (B, reactivated).
Infected cells express GFP, reactivated cells express RFP, and transduced proteins were detected with anti-myc or anti-
V5 antibodies and an anti-mouse Alexa Fluor 647 coupled antibody (pink). Nuclei were counterstained with Hoechst
(blue). Images are representative of at least 2 independent experiments. Scale bar = 10 μm.
https://doi.org/10.1371/journal.ppat.1006937.g004
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Fig 5. The interaction of ORF20 with OASL is conserved among the members of the UL24 family. (A) HeLa cells were transfected with the indicated
plasmid and seeded onto coverslips. 48 h post transfection, coverslips were fixed in PFA and processed for anti-myc (green) and anti-fibrillarin (red)
immunofluorescence. Nuclei were counterstained with Hoechst (blue). Images are representative of three independent experiments. Scale bar = 10 μm (B)
293T cells were transfected with myc-tagged UL24, UL76, M76, or ORF20WT. Lysates were prepared 24 h later, separated by SDS-PAGE, and anti-myc and
anti-tubulin immunoblotting was performed. Data are representative of four independent experiments. (C) 293T cells were transfected with the indicated
myc-tagged KSHV ORF20 form or MHV68 ORF20. An anti-myc immunoprecipitation of RIPA lysates was performed and input lysates and
immunoprecipitates were immunoblotted with an anti-myc antibody. Data are representative of two independent experiments. (D) 293T cells were
transfected with myc-tagged UL24 homologs MCMV M76, HCMV UL76, or HSV-1 UL24, LacZ-myc, OASL-V5, and/or EV as indicated. An anti-myc
immunoprecipitation of RIPA lysates was performed and input lysates and immunoprecipitates were immunoblotted with anti-V5 and anti-myc
antibodies. Data are representative of two independent experiments.
https://doi.org/10.1371/journal.ppat.1006937.g005
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R196E/K200E (RKRK), K63E, and K66E; and three catalytic triad mutants, E81A, E83A, and
T152A, based on homology with the catalytic site of the OAS family enzymes [21] (Fig 6A).
We also used OAS1, which is enzymatically-active and lacks the UBL domains, as a control in
Fig 6. OASL RNA binding and ubiquitin-like domains are not required for interaction with ORF20. (A) Multiple OASL constructs were utilized, including WT
OASL and OASL mutants, including ΔUBL lacking the ubiquitin-like domain, the P-loop mutants V67G and N72K, the RNA binding mutants R45E/K66E/R196E/
K200E (RKRK), K63E, and K66E, and the catalytic triad mutants, E81A, E83A, and T152A. (B) 293T cells were transfected with myc-tagged ORF20WT or LacZ,
V5-tagged OAS1, WT or mutant OASL, and/or empty vector (EV) as indicated. An anti-myc immunoprecipitation of RIPA lysates was performed and input lysates and
immunoprecipitates were immunoblotted with anti-V5 and anti-myc antibodies. Immunoblots are representative of at least three independent experiments. Similar
results were obtained with simultaneous and sequential antibody exposures. (C) The amino acid sequence for ORF20B is shown, with the predicted nuclear localization
sequence indicated in red, the predicted nucleolar localization sequence indicated in green, and predicted disordered regions underlined. The predictions formed the
basis for three ORF20B C-terminal truncation mutants: ORF20B 1–186, 1–220, and 1–235. (D) 293T cells were transfected with myc-tagged ORF20 isoforms, ORF20B
mutants, or LacZ, OASL-V5, and/or EV as indicated. An anti-myc immunoprecipitation of RIPA lysates was performed. Input lysates and immunoprecipitates were
immunoblotted with anti-V5 and anti-myc antibodies. Immunoblots are representative of three independent experiments.
https://doi.org/10.1371/journal.ppat.1006937.g006
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our interaction studies. We co-transfected myc-tagged ORF20WT with V5-tagged OAS1, WT
OASL, or the various OASL mutants and verified their expression in input lysates (Fig 6B). All
constructs were expressed, although OAS1 and OASLΔUBL were weakly expressed compared
to WT OASL. We then performed an anti-myc immunoprecipitation and found that WT
OASL and all OASL mutants co-immunoprecipitated with ORF20WT, but not with the nega-
tive control LacZ (Fig 6B). OASLΔUBL, despite its weaker expression compared to WT OASL,
also co-immunoprecipitated with ORF20WT, but OAS1 did not, confirming the specificity of
the interaction between ORF20 and OASL. We next verified the subcellular localization of all
OASL constructs by whole-cell and nuclear immunofluorescence, and found that with the
exception of OASLΔUBL, which was weakly expressed and detected in the cytoplasm and
nuclei, all constructs were localized to the cytoplasm and nucleoli (S4 Fig).
As all three ORF20 isoforms immunoprecipitated OASL, we next wanted to identify the
region of ORF20B required for interaction with OASL. Based on secondary structure and
nuclear and nucleolar localization sequence predictions (Fig 6C), we created three ORF20B
deletion mutants: ORF20B 1–235, 1–220, and 1–186 (Fig 6C). We co-transfected the myc-
tagged ORF20 isoforms WT, FL, A, or B, ORF20B deletion mutants, or LacZ as a control with
V5-tagged OASL. OASL and all ORF20 isoforms and truncation mutants were expressed in
input lysates as expected (Fig 6D). We then performed an anti-myc immunoprecipitation and
found that OASL co-immunoprecipitated with all ORF20B deletion mutants, suggesting that
the first 186 amino acids of ORF20B are important for the interaction with OASL (Fig 6D).
We then verified the subcellular localization of all ORF20B deletion mutants and found that all
mutants localized to the nuclei and nucleoli (S5 Fig). These data suggest that the predicted
nuclear and nucleolar localization sequences (Fig 6C) are not exclusively required for ORF20
localization. In summary, neither the ubiquitin-like domains nor RNA binding functions of
OASL are required for the interaction with ORF20, and the interaction of ORF20 with OASL
can be mapped to amino acids 1–186 of the smallest isoform, ORF20B.
OASL and ORF20 share very similar interactomes
To better understand why ORF20 and OASL may interact, we utilized unbiased q-AP-MS to
identify interaction partners of OASL. Using an experimental setup similar to that for ORF20
(Fig 3A), we identified numerous interacting partners of OASL (Fig 7A, Table 2, S2 Dataset),
of which many were 40S or 60S ribosomal proteins or nucleolar proteins. We also identified
proteins with anticipated functions in ribosome biogenesis (Table 2, S2 Dataset). Next, we
compared the proteins identified as interacting partners of ORF20 and OASL (Table 1 and
Table 2). We identified 14 proteins that copurified with ORF20 only and 49 proteins that
copurified exclusively with OASL. Interestingly, 33 proteins were identified as interacting part-
ners for both ORF20 and OASL (Fig 7B and S1 Supporting Information).
ORF20 and OASL co-sediment with ribosomal subunits and polysomes
The nucleoli are the sites of ribosome biogenesis. Based on the nucleolar localization of ORF20
and OASL, as well as on their numerous shared nucleolar and ribosomal interacting partners,
we wanted to verify whether ORF20 and OASL co-sediment with ribosomal subunits and/or
polysomes. We performed sucrose gradient fractionation of ribosomes from cells expressing
ORF20WT, OASL, or both ORF20WT and OASL together. Ribosomes were purified either in
the presence of EDTA, which causes the dissociation of ribosomes into small (40S) and large
(60S) subunits, or in the presence of MgCl2 to stabilize 80S ribosomes and polysomes. The
absorbance at 254 nm was measured to identify the fractions containing subunits, ribosomes,
and polysomes (Fig 8). The fraction identification was further verified by analyzing the 18S
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and 28S rRNA content; 18S rRNA was present in the 40S subunit fractions and 28S rRNA in
the 60S subunit fractions. We found that when expressed alone, ORF20WT and OASL individ-
ually copurified with 40S and 60S ribosomal subunits (Fig 8A and 8C). ORF20WT weakly
copurified with 80S ribosomes and polysomes (Fig 8B) and OASL copurified with 80S ribo-
somes when expressed alone (Fig 8D).
When co-expressed, ORF20WT and OASL copurified with 40S and 60S ribosomal subunits
(Fig 8E), as well as with polysomes (Fig 8F). In summary, the co-sedimentation of ORF20WT
and OASL with the 40S and 60S ribosomal subunits verifies our identification of 40S and 60S
ribosomal subunit proteins as specific interaction partners of ORF20WT and OASL. Further-
more, the association of ORF20WT and OASL with polysomes suggests that these proteins
may affect protein translation.
ORF20 and OASL do not globally affect translation
To analyze whether ORF20WT and OASL have global effects on cellular translation, we uti-
lized a puromycin incorporation assay [34]. 293T cells were transfected with EV, ORF20WT,
ORF20FL, or ORF20B, and either EV as a control or RIG-I N to induce expression of endoge-
nous OASL. 24 h post transfection, cells were treated for 15 minutes with puromycin to allow
incorporation into nascent proteins, then immediately lysed in sample buffer. Lysates were
then subjected to anti-puromycin, anti-OASL, anti-myc, and anti-actin immunoblotting.
Expression of ORF20 did not affect translation rates, as incorporation of puromycin was simi-
lar across all samples both in the absence and presence of RIG-I N (Fig 9A). As expected, we
did not detect endogenous OASL unless RIG-I N was transfected. In addition, we did not
observe global changes in translation upon OASL expression, as translation rates were similar
in EV and RIG-I N transfected cells (Fig 9A). Interestingly, the amount of OASL protein was
slightly increased when ORF20 forms were present (Fig 9A).
Fig 7. Quantitative proteomics identified nucleolar and ribosomal interaction partners of OASL. (A) q-AP-MS was performed as shown in Fig 3A. For the
forward experiment, heavy-labeled HeLa S3 cells were transfected with OASL-myc and light-labeled cells were transfected with LacZ-myc. In the crossover
experiment, OASL-myc was labeled with light amino acids and LacZ-myc with heavy amino acids. Cell lysates were immunoprecipitated with anti-myc magnetic
beads and analyzed by LC-MS/MS. Specific interacting partners of OASL identified in both the forward and crossover experiments are located in the lower right
quadrant. 40S and 60S ribosomal proteins are shown in blue and nucleolar proteins are indicated in green. (B) The interacting partners shown in Tables 1 and 2
were compared using VennDis to determine the number of specific and shared interacting partners for ORF20 and OASL (related to S1 Supporting
Information).
https://doi.org/10.1371/journal.ppat.1006937.g007
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Table 2. OASL interacting partners identified by q-AP-MS.
Protein Log2 forward Log2 crossover
Ribosome production factor 2 homolog 3,388 -2,682
60S ribosomal protein L36 2,875 -2,727
40S ribosomal protein S10 2,858 -2,546
RNA-binding protein 34 2,838 -2,419
60S ribosomal protein L5 2,784 -2,782
Ubiquitin-40S ribosomal protein S27a 2,782 -2,403
Probable rRNA-processing protein EBP2 2,776 -2,193
60S ribosomal protein L10a 2,754 -2,453
40S ribosomal protein S28 2,753 -2,635
RNA-binding protein 28 2,747 -2,026
60S acidic ribosomal protein P0 2,698 -2,403
40S ribosomal protein S3 2,696 -2,544
40S ribosomal protein S12 2,675 -2,592
40S ribosomal protein S18 2,673 -2,712
40S ribosomal protein S16 2,672 -2,546
60S acidic ribosomal protein P1 2,671 -2,498
60S ribosomal protein L12 2,664 -2,553
Putative ribosomal RNA methyltransferase NOP2 2,656 -1,874
40S ribosomal protein S25 2,642 -2,567
60S ribosomal protein L8 2,631 -2,285
Ribosome biogenesis protein BRX1 homolog 2,614 -4,226
60S ribosomal protein L18a 2,614 -2,606
60S ribosomal protein L21 2,604 -2,550
60S ribosomal protein L34 2,601 -2,464
60S ribosomal protein L7 2,592 -1,567
60S acidic ribosomal protein P2 2,591 -2,371
60S ribosomal protein L30 2,582 -2,449
40S ribosomal protein S5 2,582 -4,397
60S ribosomal protein L35a 2,571 -2,194
60S ribosomal protein L28 2,558 -2,627
40S ribosomal protein S20 2,546 -2,635
60S ribosomal protein L14 2,541 -2,329
60S ribosomal protein L6 2,505 -2,508
60S ribosomal protein L7a 2,457 -2,470
60S ribosomal protein L27 2,453 -2,423
60S ribosomal protein L32 2,444 -2,497
60S ribosomal protein L3 2,423 -2,058
40S ribosomal protein S17-like 2,422 -2,144
60S ribosomal protein L4 2,419 -1,704
60S ribosomal protein L11 2,415 -2,318
Uncharacterized protein C7orf50 2,408 -2,409
60S ribosomal protein L13a 2,384 -2,028
Nucleolar RNA helicase 2 2,371 -1,632
60S ribosomal protein L18 2,368 -1,811
60S ribosomal protein L15 2,285 -1,836
60S ribosomal protein L37a 2,244 -1,956
60S ribosomal protein L13 2,228 -2,319
(Continued)
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ORF20 enhances OASL transcription
To determine whether ORF20 affects OASL mRNA expression, we used quantitative reverse
transcriptase polymerase chain reaction (q-RT-PCR) to measure OASL mRNA levels in trans-
fected 293T cells. As expected, OASL mRNA levels were upregulated in the presence of RIG-I
N (Fig 9B). In addition, we observed a further significant increase in OASL mRNA levels when
Table 2. (Continued)
Protein Log2 forward Log2 crossover
Ribosome biogenesis regulatory protein homolog 2,202 -2,221
40S ribosomal protein S15 2,162 -2,013
Eukaryotic translation initiation factor 6 2,111 -2,093
Putative oxidoreductase GLYR1 2,096 -1,492
Ataxin-2-like protein 2,023 -1,259
Ribosomal L1 domain-containing protein 1 2,001 -1,737
60S ribosomal protein L29 1,895 -1,952
Coiled-coil domain-containing protein 137 1,838 -1,235
Nuclease-sensitive element-binding protein 1 1,823 -2,181
60S ribosomal protein L24 1,803 -1,612
40S ribosomal protein S2 1,772 -1,653
Fragile X mental retardation syndrome-related protein 1 1,754 -1,507
Protein LLP homolog 1,751 -1,708
60S ribosomal protein L10 1,741 -1,616
60S ribosomal protein L9 1,640 -1,692
Y-box-binding protein 3 1,593 -1,728
Exosome complex component RRP46 1,578 -1,319
Double-stranded RNA-binding protein Staufen homolog 2 1,554 -1,874
60S ribosomal protein L23 1,526 -1,600
Polyadenylate-binding protein 1 1,520 -1,670
Elongation factor 1-alpha 1 1,508 -0,443
RNA-binding protein 10 1,502 -0,615
40S ribosomal protein S14 1,497 -1,739
40S ribosomal protein S8 1,487 -1,458
rRNA 2’-O-methyltransferase fibrillarin 1,480 -1,555
M-phase phosphoprotein 6 1,468 -1,491
60S ribosomal protein L19 1,331 -1,279
Nucleolar protein 16 1,249 -1,133
ATP-dependent RNA helicase A 1,246 -1,054
40S ribosomal protein S23 1,190 -1,270
Centromere protein V 1,181 -1,913
Heat shock protein beta-1 1,171 -1,197
60S ribosomal protein L27a 1,150 -1,245
40S ribosomal protein S6 1,138 -1,150
Heterochromatin protein 1-binding protein 3 1,133 -1,042
Vimentin 1,112 -1,006
40S ribosomal protein S3a 1,082 -1,349
Highly confident interaction partners were based on log2 fold change values with an absolute value1 in one
experiment and 0.7 in the other experiment. The complete list can be found in S2 Dataset.
https://doi.org/10.1371/journal.ppat.1006937.t002
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Fig 8. ORF20 and OASL copurify with ribosomal subunits and polysomes. 293T cells were cotransfected with myc-tagged ORF20 (A-B), OASL
(C-D), or ORF20 and OASL together (E-F), then ribosomes were purified by 5–45% sucrose gradient fractionation in the presence of EDTA (A, C, E) or
MgCl2 (B, D, F). Fractionation profiles were determined by absorbance at 254 nm. 40S and 60S indicate the small and large ribosomal subunits,
respectively, and 80S indicates the monosome peak. Fractions were collected and analyzed for 18S and 28S rRNA by denaturing gel electrophoresis and
for OASL and ORF20 expression by anti-myc immunoblotting. Results are representative of two independent experiments.
https://doi.org/10.1371/journal.ppat.1006937.g008
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ORF20WT and RIG-I N were expressed (Fig 9B). As specificity controls, we included addi-
tional nuclear KSHV ORFs in this assay. Unlike for ORF20WT, compared to EV with RIG-I
N, we observed no upregulation of OASL mRNA levels in cells co-expressing RIG-I N and
either ORF59, K8.1, ORF27, or RTA (S6A Fig). We also included vIRF1 as a known inhibitor
of IRF3 [35], and observed reduced OASL levels as expected (S6A Fig). Next, we determined
Fig 9. ORF20 does not affect translation rates, but enhances expression of endogenous OASL. (A) 293T cells were co-transfected with EV, myc-tagged
ORF20WT, ORF20FL, or ORF20B, and either EV or RIG-I N. 24 h post transfection, cells were treated for 15 minutes with 5μg/ml puromycin, then lysed and
analyzed by immunoblotting. Anti-puromycin, anti-OASL, anti-myc, and anti-actin immunoblotting was performed sequentially. Data are representative of two
independent experiments. : Nonspecific background band. (B) 293T cells were co-transfected with EV or ORF20WT-myc, and either EV or RIG-I N, for 24h. (C)
HEK293 cells were transfected with either EV or ORF20WT-myc. 24h later, cells were transfected with 5’pppRNA complexed with Lipofectamine 2000 for
approximately 24h. (D) 293T cells were reverse transfected with control, IRF3, IFNAR, or STAT1 siRNAs as indicated. 48h later, cells were transfected with EV or
ORF20WT-myc, and either EV or RIG-I N, for 24h. (B, C, D) Cells were lysed, RNA was isolated, mRNA-specific cDNA was reverse transcribed, and the amount of
OASL was determined using relative quantification to GAPDH levels and the 2-ΔΔCT method. Data shown are means + SD of combined duplicates from at least two
experiments. ns, not significant,  P<0.05,  P<0.01,  P<0.001.
https://doi.org/10.1371/journal.ppat.1006937.g009
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whether ORF20 also enhanced OASL expression when endogenous RIG-I was stimulated. For
this, we utilized HEK293 cells with functional RIG-I signaling, transfected them with empty
vector or ORF20WT, and stimulated the cells with 5’pppRNA to activate the RIG-I signaling
cascade (Fig 9C). We found that OASL mRNA levels were significantly upregulated upon
5’pppRNA stimulation, and as with RIG-I N (Fig 9B), OASL mRNA levels were significantly
increased in the presence of ORF20WT (Fig 9C).
As OASL expression can be induced directly by IRF3 as well as via IFNAR signaling [13],
we wanted to elucidate the mechanism required for enhanced expression of OASL in the pres-
ence of ORF20. To do so, we used siRNA to knockdown IRF3, IFNAR, or STAT1 expression,
then transfected cells with combinations of empty vector, ORF20WT, and/or RIG-I N. In con-
trol siRNA-transfected cells, we observed upregulation of OASL in the presence of ORF20WT
and RIG-I N (Fig 9D), as shown previously (Fig 9B). In cells transfected with siRNA targeting
IRF3, IRF3 was efficiently knocked down (S6B Fig) and upregulation of OASL was completely
abrogated (Fig 9D). Next, we analyzed the effect of IFNAR and STAT1 knockdown on the abil-
ity of ORF20WT to upregulate OASL mRNA levels and found that neither IFNAR nor STAT1
knockdown affected upregulation of OASL mRNA levels (Fig 9D), although expression of
both was efficiently inhibited (S6C and S6D Fig, respectively).
In summary, these results suggest that although ORF20 does not globally affect translation,
it affects expression of endogenous OASL at both the mRNA and protein levels, and ORF20-
mediated upregulation of OASL mRNA expression is IRF3- but not IFNAR-dependent.
ORF20 does not affect the interaction between OASL and RIG-I
As OASL has been shown to interact and co-localize with RIG-I [18], we next analyzed
whether ORF20 affected the interaction or co-localization of OASL with RIG-I. First, we ana-
lyzed interactions in transiently transfected 293T cells lysed under milder conditions than
those used for S2 Fig. OASL co-immunoprecipitated with RIG-I in both the presence and
absence of ORF20WT (S7A Fig). ORF20WT did not interact with RIG-I in the absence of
OASL, but did co-immunoprecipitate with RIG-I in the presence of OASL, suggesting the
detected interaction was due to OASL binding both RIG-I and ORF20WT (S7A Fig).
Our analysis of the subcellular localization of RIG-I, OASL, and ORF20WT in HeLa S3 cells
showed that RIG-I was located in the cytoplasm, as expected, OASL was in the cytoplasm and
nucleoli, and ORF20WT in the nuclei and nucleoli (S7B Fig) as shown previously (Fig 3E and 3F,
Fig 4, S1 Fig). When RIG-I and OASL were co-expressed, their subcellular localization did not
change, and OASL and RIG-I co-localized in the cytoplasm (S7B Fig) as reported [18]. Co-expres-
sion of ORF20WT and RIG-I did not alter their subcellular localization, nor did they co-localize
(S7B Fig). When RIG-I, OASL, and ORF20WT were co-expressed, neither their individual subcel-
lular localization, nor the co-localization between ORF20WT and OASL in the nucleoli, nor the
co-localization between RIG-I and OASL in the cytoplasm, was affected (S7C Fig). Co-localization
between ORF20WT and RIG-I was also not observed in the presence of OASL (S7C Fig).
OASL is proviral for gammaherpesviral infection
ISGs can have pro- and anti-viral effects [15]. Although OASL has been identified as an antivi-
ral protein against multiple viruses, it has targeted antiviral specificity [15, 16]. To verify the
antiviral function of OASL in a reconstitution assay, we infected 293T OASL-/- cells reconsti-
tuted with EV or hOASL with vesicular stomatitis virus expressing GFP (VSV-GFP) (Fig 10A
and 10B) and determined the GFP signal by flow cytometry 16 h post infection. Compared to
the mean fluorescence intensity (MFI) of GFP in EV-transfected cells, we observed a decrease
in MFI when hOASL was expressed (Fig 10A). We observed a corresponding significant
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decrease in the number of GFP-high cells when hOASL was expressed (Fig 10B), confirming
the antiviral effect of OASL during VSV infection [18].
OASL has not been characterized for its role during gammaherpesviral infection. We there-
fore determined the effect of OASL expression on gammaherpesviral growth and infectivity.
Fig 10. OASL expression is beneficial for MHV68 and KSHV replication. (A-F, H) 293T OASL-/- cells were reconstituted with empty vector (EV), mOASL1, or
hOASL as indicated. (A-B) 24 h later, cells were infected with VSV-GFP for 16 h. The GFP intensity in fixed cells was determined by flow cytometry. (A)
Histograms of the VSV-GFP signal for duplicates from one representative experiment are shown. (B) The number of highly-GFP positive cells was determined and
scaled to EV. Means + SD of duplicates from two independent experiments are shown. (C-D) 24 h post transfection, cells were infected with MHV68-GFP at an
MOI of 0.05 for 2 h at 37˚C. Supernatant was harvested at the indicated times and the viral titer was determined by TCID50 on M2-10B4 cells. Means ± SD of
triplicates from two independent experiments are shown. (E, F, H) 24 h post transfection, cells were infected with (E) MHV68-GFP, (F) KSHVLYT wildtype, or (H)
KSHVLYT ORF20stop. 20–24 h later, cells were detached, fixed, and the number of GFP-positive cells was determined by flow cytometry. Means + SD of 4–6
replicates total from two independent experiments are shown. (G) In KSHVLYT ORF20stop, the ORF20 GAG codon for E69 is replaced with the stop codon TAG.
For all subfigures: ns, not significant,  P<0.05, P<0.01,  P<0.001.
https://doi.org/10.1371/journal.ppat.1006937.g010
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First, we reconstituted 293T OASL-/- cells with the murine homolog of OASL, mOASL1 (Fig
10C), human OASL (Fig 10D), or empty vector (EV) as a control. We then infected cells with
MHV68-GFP at a low multiplicity of infection (MOI) and performed growth curves over sev-
eral days. When either mOASL1 or hOASL was expressed, viral growth was enhanced com-
pared to cells transfected with EV (Fig 10C and 10D). We then reconstituted 293T OASL-/-
cells with mOASL1 or hOASL, infected them with MHV68-GFP at a high MOI, and quantified
the number of infected GFP-positive cells by flow cytometry 20 h post infection. We found
that the number of GFP-positive cells was significantly increased in samples expressing
mOASL1 or hOASL, compared to cells transfected with EV (Fig 10E).
We next performed a similar experiment with KSHV. As KSHV infection in vitro fre-
quently defaults to latency and ORF20 is a lytic gene, we used a genetically modified form of
KSHV. In KSHVLYT, the viral replication and transcription activator RTA is under control of
a constitutively active PGK promoter, leading to exclusively lytic replication [36, 37]. We
infected 293T OASL-/- cells reconstituted with either EV or hOASL with wildtype KSHVLYT
and used flow cytometry to quantify the number of infected cells 24 h post infection. We
found that the number of GFP-positive cells was significantly increased in the presence of
hOASL (Fig 10F). Our data show that OASL is beneficial for both MHV68 and KSHVLYT
infection.
To determine whether the proviral effect of OASL is dependent on the presence of ORF20,
we used en passant mutagenesis to generate an ORF20stop virus on the KSHVLYT background.
To avoid affecting the ORF21 protein sequence or identified ORF21 promoter transcription
factor binding sites, we changed the codon for E69, GAG, to the stop codon TAG (Fig 10G).
While the first 69 amino acids of ORF20FL may be expressed, only 5 amino acids of ORF20B
can be expressed. We infected 293T OASL-/- cells reconstituted with either EV or hOASL with
KSHVLYT ORF20stop. We found that the number of GFP-positive cells was similar in both EV
and hOASL reconstituted cells (Fig 10H), in contrast to the enhancement of infection observed
for KSHVLYT wildtype (Fig 10F). These data suggest that ORF20 contributes to the beneficial
effect of hOASL on KSHVLYT.
OASL and ORF20 mRNA are expressed in reactivated HuARLT2-
rKSHV.219 cells
OASL is expressed upon de novo infection with KSHV [38], but to date, the expression of
OASL upon reactivation of KSHV-infected cells has not been well characterized. To determine
whether OASL is expressed upon reactivation, we treated HuARLT-rKSHV.219 cells with
sodium butyrate and RTA-expressing baculovirus to induce lytic reactivation, then collected
samples for RNA isolation at 6 and 24 h. As a control, we included uninfected HuARLT2 cells.
We then measured OASL and lytic transcript levels by q-RT-PCR. Compared to uninfected
cells, OASL mRNA was increased in latently infected cells (Fig 11A). Upon reactivation, OASL
mRNA expression significantly increased (Fig 11A). To analyze expression of lytic viral genes,
we compared mRNA levels of ORF20, ORF16, OF46, and K8.1 in latently infected and reacti-
vated cells. Based on de novo infection of endothelial cells and reactivation of latently infected
BCBL-1 cells, ORF16 is classified as immediate early, ORF46 as early, K8.1 as late, and ORF20
as late [11, 39, 40]. We found that in HuARLT2-rKSHV.219 cells, ORF20 (Fig 11B) and
ORF16 (Fig 11C) expression was already increased as early as 6h post reactivation, with expres-
sion further increasing at 24h. In contrast, very little ORF46 (Fig 11D) or K8.1 (Fig 11E) was
detected at 6h post reactivation, but levels were greatly increased at 24h. Our data show that
OASL and ORF20 mRNA expression are increased concomitantly during reactivation of
HuARLT2-rKSHV.219 cells.
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In summary, we have identified the cellular protein OASL as an interacting partner of
KSHV ORF20 by q-AP-MS and identified novel interactions of ORF20 and OASL with ribo-
somal and nucleolar proteins. We characterized the conserved interaction of ORF20 isoforms
and homologs with OASL, and we used a variety of mutants to further characterize the interac-
tion of ORF20 with OASL. We found that both ORF20 and OASL co-sediment with ribosomal
subunits. While ORF20 did not globally enhance translation, ORF20 expression strongly
increased expression of endogenous OASL in an IRF3-dependent manner. Both OASL and
ORF20 are expressed upon lytic reactivation of cells latently infected with KSHV. Finally, the
presence of OASL enhances KSHV infectivity in an ORF20-dependent manner, suggesting a
novel viral mechanism for usurping control of the host cell environment.
Discussion
In this study, we have characterized the three protein isoforms of KSHV ORF20WT:
ORF20FL, ORF20A, and ORF20B. We have found that like ORF20WT [10], all three ORF20
isoforms predominantly localize to the nuclei and nucleoli of transiently transfected cells.
ORF20 is classified as a late lytic protein based on detection of ORF20 mRNA at late time
Fig 11. OASL and ORF20 are expressed in reactivated HuARLT2-rKSHV.219 cells. Uninfected HuARLT2 and latently infected HuARLT2-rKSHV.219
cells were seeded in 6-well plates. HuARLT2-rKSHV.219 cells were untreated (-) or reactivated by addition of sodium butyrate and RTA-expressing
baculovirus, then incubated for the indicated times. RNA was prepared and (A) OASL (B) ORF20 (C) ORF16 (D) ORF46 or (E) K8.1 mRNA levels were
determined by q-RT-PCR. The averages + SD of duplicates from 1 representative of 3 total experiments are shown. nd, not detected, ns, not significant, 
P<0.01, P<0.001.
https://doi.org/10.1371/journal.ppat.1006937.g011
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points post de novo infection of endothelial cells or lytic reactivation of BCBL-1 cells [40] [11,
39]. We analyzed the expression of ORF20 mRNA upon lytic reactivation of endothelial cells,
and found that it was expressed similarly to ORF16, which is classified as an immediate-early
gene. This difference in expression may be due to reactivation versus de novo infection of
endothelial cells, or due to differences in expression upon reactivation of endothelial versus B
cells. This is not unusual for KSHV proteins; for example, K15 expression is very different in B
cells and endothelial cells [29]. ORF20 is a member of the herpesviral UL24 family and the sub-
cellular localization of all ORF20 isoforms was similar to the localization reported for multiple
members of the UL24 family [9, 10].
As ORF20 is a poorly characterized protein, we wanted to better understand its function.
We utilized an unbiased q-AP-MS approach to identify specific interacting partners of ORF20.
During the course of our experiments, a global mapping study identified interacting partners
of 89 KSHV proteins [41]. The authors identified high-confidence interactions using a mass
spectrometry interaction statistics scoring algorithm that they developed, and identified one
interacting partner for KSHV ORF20: coiled-coil domain containing protein 86 (CCDC86),
also known as cytokine-induced protein with coiled-coil domain or cyclon [41]. The function
of CCDC86 is not well understood. It localizes to the nuclei and nucleoli, is induced by IL-3
expression, and is involved in maintenance of T-cell homeostasis [42–44]. In our analysis of
ORF20 interacting partners, we did not identify CCDC86. This may be due to differences in
the cell type used, as we used HeLa S3, not 293T cells, or differences in the analysis method, as
we used stable isotope labeling in cell culture for our q-AP-MS.
We found that ORF20 specifically interacted with the ISG oligoadenylate synthetase-like
protein OASL. This is the first known interaction of a viral protein with OASL. We character-
ized the interaction of ORF20WT with a variety of OASL mutants and found that the interac-
tion occurred independently of RNA-binding and the ubiquitin-like domain of OASL.
Whether nucleolar localization of OASL is exclusively required for its interaction with
ORF20WT is still unclear, as the expression of the OASLΔUBL mutant was low and thus
nucleolar localization may have been obscured. We used C-terminal truncation mutants of the
shortest ORF20 isoform, ORF20B, and found that the shortest mutant, ORF20B 1–186, was
still able to bind wild-type OASL and localize to nucleoli.
Although the role of OASL during KSHV infection has not previously been studied directly,
microarray analysis of cellular mRNA expression upon KSHV infection has shown that OASL
expression is induced at late time points upon de novo KSHV infection [38]. We now show
that OASL mRNA expression is increased in latently infected HuARLT2-rKSHV.219 cells
compared to uninfected cells, and OASL mRNA expression is further increased upon reactiva-
tion with concomitant ORF20 mRNA expression. The exact mechanism of OASL induction
by de novo KSHV infection or reactivation is not known, but OASL is induced by Sendai and
influenza infection in an IRF3-dependent manner [13]. OASL is also expressed as an ISG
downstream of the type I IFN receptor [13].
Until now, the effect of OASL on gammaherpesviral infection was not studied. When we
infected OASL-reconstituted cells with MHV68-GFP or KSHVLYT, we found that the number
of infected cells was significantly increased compared to EV-transfected cells. When we
infected hOASL-reconstituted 293T OASL-/- cells with KSHVLYT ORF20stop, we did not
observe enhancement of infection. However, when we infected OASL-reconstituted OASL-/-
cells with VSV-GFP, we observed inhibition of infection as expected. Taken together, these
results indicate a unique proviral role for OASL during gammaherpesviral infection.
Two previous studies have analyzed protein-protein interactions of OASL and identified
interactions with the transcriptional repressor methyl CpG binding protein 1 (MBD1) and
RIG-I [24] [18]. However, no q-AP-MS data was available. When we analyzed the OASL
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interactome, we found that it was very similar to what we identified for ORF20, and in agree-
ment with their nucleolar localization. We found that 40S and 60S ribosomal proteins were
robustly represented among the identified interaction partners of both ORF20 and OASL.
Ribosomal proteins are often considered contaminants in standard affinity purification mass
spectrometry analysis and many ribosomal proteins are listed in the “contaminant repository
for affinity purification”, or CRAPome [45]. However, q-AP-MS allows identification of ribo-
somal proteins as specific interaction partners. True interaction partners are identified by their
specific abundance ratio for the bait protein, while non-specific contaminants can be identified
based on their equal binding affinity for the bait and control proteins. The identification of
ribosomal proteins for both ORF20 and OASL is thus of interest for elucidation of the func-
tions of ORF20 and OASL.
To further characterize the interactions of ORF20 and OASL with ribosomes, we utilized a
ribosomal sedimentation assay to analyze the association of both proteins with ribosomes.
Both proteins sedimented with 40S and 60S ribosomal subunits when expressed individually
and in combination with each other, further validating the protein interactions we identified
by q-AP-MS. Interestingly, we found that when ORF20 and OASL were co-expressed, both
proteins associated with polysomes. This may be due to increased expression when both were
co-expressed, although recruitment to polysomes cannot be excluded. As association with
polysomes may globally or selectively affect translation, we used a puromycin termination
assay to examine the effect of ORF20 and OASL on cellular translation [34]. We found that
puromycin was incorporated similarly in all samples. Taken together, the association with
polysomes and similar incorporation of puromycin suggest selective control of gene expres-
sion. We found that endogenous OASL and ORF20 mRNA expression were increased con-
comitantly during reactivation of HuARLT2-rKSHV.219 cells. Additionally, we found that the
OASL mRNA level was further upregulated upon RIG-I N overexpression or stimulation of
endogenous RIG-I when ORF20 was present. We used siRNA knockdown to analyze the sig-
naling components required for upregulation of OASL mRNA, and found that upregulation of
OASL mRNA levels by ORF20 was IRF3- but not IFNAR-dependent. It is plausible that
ORF20 enhances OASL expression at the mRNA level to allow sufficient protein levels for
ORF20 to utilize OASL.
Regulation of gene expression occurs at many levels in eukaryotic cells. Transcriptional and
post-transcriptional regulation are two major factors. Additionally, emerging evidence sug-
gests that rather than possessing intrinsic translational capabilities, ribosomes contribute to
control of gene expression. A recent publication has shown that translating ribosomes vary in
their ribosomal protein composition, bestowing translational selectivity [46]. There are at least
80 different ribosomal proteins, and furthermore ribosomal RNA bases and ribosomal pro-
teins can be modified. The number of possible ribosomes is therefore enormous [47]. Viral
modulation of ribosome formation to form specialized ribosomes is one potential mechanism
that viruses could use to enhance production of viral proteins and necessary cellular factors.
By manipulating the incorporation of specific ribosomal proteins, a virus could promote trans-
lation of desirable mRNAs. It is possible that ORF20 increases expression of OASL to allow
both proteins to contribute to formation of specialized ribosomes and translational control,
which is an exciting topic for future study.
Materials and methods
Cell culture
Human embryonic kidney 293T (CRL-3216), human embryonic kidney 293 (CRL-1573), pri-
mary human foreskin fibroblast HFF-1 (SCRC-1041), human epithelial adenocarcinoma HeLa
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(CCL-2) and HeLa S3 (CCL-2.2), immortalized retinal pigment epithelial hTERT RPE-1
(CRL-4000), murine bone marrow fibroblast M2-10B4 (CRL-1972), African green monkey
kidney Vero (CCL-81), and baby hamster kidney BHK-21 (CCL-10) cells were originally
obtained from the American Type Culture Collection (ATCC). 293T OASL-/- and correspond-
ing control 293T cells were kindly provided by Veit Hornung (Ludwig Maximilians Universi-
ta¨t, Munich, Germany) [18]. Conditionally immortalized human endothelial cells stably
infected with rKSHV.219, HuARLT2-rKSHV.219, and corresponding uninfected HuARLT2
control cells [29, 31, 48] were kindly provided by Thomas F. Schulz (Hannover Medical
School, Hannover, Germany). HuARLT-rKSHV.219 and HuARLT2 cells were maintained in
Cellovations enhanced microvascular endothelial cell growth medium (PB-MH-100-4099,
PELOBiotech, Planegg, Germany) supplemented with 2 μg/ml doxycycline and for HuARLT2-
rKSHV.219 additionally 5 μg/ml puromycin. All other cell lines were maintained in basal
medium of Gibco high glucose (4.5 g/L) DMEM containing L-glutamine (ThermoFisher Sci-
entific) supplemented with 8% fetal calf serum (FCS), penicillin/streptomycin (p/s), and
sodium pyruvate; medium for HeLa and HeLa S3 additionally included 1% non-essential
amino acids (NEAA), and medium for M2-10B4 and BHK-21 cells lacked sodium pyruvate.
hTERT-RPE1 were cultured in high glucose DMEM with 5% FCS and p/s. HEK 293 were cul-
tured in high glucose DMEM with 10% FCS and p/s. HFF-1 were cultured in high glucose
DMEM supplemented with 15% FCS and p/s. Vero cells were cultured in MEM supplemented
with 7.5% FCS, glutamine, NEAA, and p/s. All cell lines were cultured at 37˚C in a humidified,
7.5% CO2 environment.
Antibodies
Antibodies against fibrillarin (# 2639), IRF3 (# 4302 for immunoblotting), STAT1 (# 9172),
and the anti-myc tag mouse monoclonal 9B11 (# 2276) were from Cell Signaling. Rabbit anti-
c-myc (# C3956), mouse anti-tubulin (# T6199-200UL), and mouse anti-beta-actin (#A5441)
antibodies were purchased from Sigma-Aldrich. The anti-puromycin antibody clone 12D10
(# MABE343) was purchased from Merck Millipore. Anti-V5 antibodies were purchased
from Invitrogen (# R960-25) and Biolegend (# 680601). Rabbit anti-GFP antibody ab290 was
purchased from Abcam and HRP-coupled mouse anti-GFP antibody (sc-9996 HRP) and anti-
IRF3 (sc-9082 for immunofluorescence) were purchased from Santa Cruz. Two rabbit poly-
clonal antibodies, anti-OASL 7 and anti-OASL 8, were raised in individual rabbits against a
C-terminal peptide of OASL, KQQIEDQQGLPKKQ, which corresponds to amino acids 460–
473 within the OASL ubiquitin-like domain.
Plasmids
pcDNA4/myc-His B, pcDNA4/myc-His/LacZ (LacZ-myc), and pcDNA3.1(+) were purchased
from Invitrogen. The LacZ-myc plasmid encodes the beta-galactosidase protein and is referred
to by the LacZ construct name throughout the text. ORF20WT was cloned into pcDNA4/myc-
His B and encodes genomic KSHV ORF20 with a C-terminal myc-tag [10]. The ORF20WT
plasmid construct can potentially express myc-tagged ORF20FL from its ATG (methionine)
start codon at nucleotide position (nt) 1, myc-tagged genomic ORF20A (gA) from its CTG
(leucine) start codon at nt 70, and myc-tagged ORF20B from its ATG start codon at nt 190.
pcDNA4/myc-His B constructs to express myc-tagged ORF20FL, ORF20A, or ORF20B indi-
vidually were made using ORF20WT as a template and utilized site-directed mutagenesis and/
or PCR based cloning. To enhance expression of ORF20A individually, an ATG was added 5’
of the genomic leucine CTG start codon. pcDNA4/myc-His B constructs expressing two myc-
tagged isoforms were also made using mutagenesis and/or PCR based cloning. ORF20FLgA
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and ORF20FLB potentially express ORF20FL and ORF20A or ORF20FL and ORF20B, respec-
tively, from their genomic start codons. ORF20AB, which can express ORF20A and ORF20B,
includes the genomic ORF20B start codon and a 5’ ATG upstream of the genomic ORF20A
start to enhance plasmid-based expression.
MHV68 ORF20 (WUMS strain, NCBI NC_001826.2) with two sequential C-terminal myc
tags was codon optimized for human expression and synthesized by Integrated DNA Technol-
ogies, then cloned into pcDNA4/myc-His B to make an MHV68 ORF20 construct with three
C-terminal myc tags. Other homologs were cloned into pcDNA4/myc-His B and have one C-
terminal myc tag. MCMV M76-myc (MCMV Smith strain, NCBI GU305914.1) and HSV-1
UL24-myc (NCBI NC_001806.1) were cloned using plasmid templates and HCMV UL76-myc
(NCBI AY446894.2) was cloned by direct PCR of an E. coli colony containing the HCMV
Merlin BAC, kindly provided by Martin Messerle (Hannover Medical School, Germany) [49].
pEGFP-RIG-I, expressing a GFP-RIG-I fusion, and pCAGGS Flag-RIG-I N (RIG-I N), ex-
pressing a constitutively active truncation mutant of RIG-I, were kindly provided by Andreas
Pichlmair (Technical University of Munich, Germany). pCMV GFP-NS1A(203–237), referred
to as GFP-NS1A, expresses GFP fused to amino acids 203–237 of influenza A/Udorn/72
encoding a nucleolar localization sequence and localizes to the nucleoli of transfected cells
[33]. GFP-NS1A was kindly provided by Ilkka Julkunen (University of Turku, Finland).
pcDNA3.1 human OASL-V5 WT (OASL-V5 or hOASL) and mutants have been previously
described [17, 21]. pcDNA3.1 murine OASL1-V5 (mOASL1) encodes the murine homolog of
human OASL (mOASL1: NM_145209.3). pcDNA3.1(+) OASL-myc (OASL-myc) expresses
human OASL with a C-terminal myc tag. When not otherwise specified in the text, OASL
refers to hOASL. ORF20WT-myc, ORF20B-myc, ORF20FL-myc, and OASL-V5 were sub-
cloned into the lentiviral expression vector pWPI puro, kindly provided by Didier Trono, and
lentiviral particles were prepared using pCMV gag-pol and pVSV-G.
Inserts of novel constructs were fully sequenced; other constructs were partially sequenced
for verification. Primer and cDNA sequences are available upon request.
BAC mutagenesis for construction of ORF20stop
We used en passant BAC mutagenesis [50] to construct an ORF20stop mutant on the constitu-
tively lytic KSHV (KSHVLYT) backbone [36, 37]. We mutated the ORF20FL GAG codon for
E69 into the stop codon TAG to stop translation of ORF20FL, ORF20A, and ORF20B without
altering the ORF21 promoter. KSHVLYT-BAC mutant clones were fully sequenced to confirm
successful mutagenesis and to exclude additional undesired mutations in the viral genome.
Virus stock preparation
BAC-derived MHV68-GFP [51] was amplified in M2-10B4 cells, concentrated by centrifuga-
tion for 2 h at 26,000 ×g and 4˚C, purified by pelleting through a 10% Nycodenz cushion for 3
h at 36,000 ×g, and resuspended in sterile virus standard buffer (50 mM Tris-HCl, pH 7.8, 12
mM KCl, 5 mM Na2-EDTA) essentially as previously described [36]. For reconstitution of
KSHVLYT wildtype or ORF20stop, BAC DNA was transfected into hTERT RPE-1 cells using
Polyfect (Qiagen), propagated in the same cells, and concentrated by centrifugation for 4 h at
15,000 ×g at 4˚C. Viral stock titers were determined using the median tissue culture infective
dose (TCID50) method on M2-10B4 cells and hTERT-RPE1 cells for MHV68 and KSHVLYT,
respectively, as previously described [36, 37]. Vesicular stomatitis virus with GFP inserted
between the G and L genes [52] was kindly provided by Andrea Kro¨ger (Otto von Guericke
University Magdeburg, Germany). VSV-GFP was amplified in BHK-21 cells and the stock
titer was determined by plaque assay on Vero cells. Lentiviral particles were prepared by co-
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transfection of low-passage 293T cells in 6 well plates with 2 μg of the appropriate pWPI
expression vector, 1.3 μg pCMV gag-pol, and 700 ng VSV-G; DNA was complexed with 10 μl
Lipofectamine 2000.
Approximately 16 h post transfection, medium was changed to viral harvest medium (high
glucose DMEM containing 20% FCS, p/s, and 10 mM HEPES). The following day, approxi-
mately 40–44 h post transfection, supernatants were filtered through 0.45 μm filters and used
immediately for transduction.
Immunoprecipitations
Transfected cells were lysed in mild NP-40 lysis buffer, containing 50 mM Tris-HCl, pH 7.4,
150 mM NaCl, 1% IGEPAL CA-630 (NP-40 substitute), 0.25% sodium deoxycholate, and 1x
complete protease inhibitors without EDTA (Roche), or stringent radioimmunoprecipitation
(RIPA) buffer containing 20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA, 1% Triton
X-100, 0.5% sodium deoxycholate, 0.1% SDS, and 1x complete protease inhibitors (Roche).
One-tenth of the lysate was reserved as input lysate, the remainder was pre-cleared with pro-
tein A agarose beads (Repligen), immunoprecipitated (IP) with anti-myc, anti-V5, or anti-
GFP antibodies, and then incubated with protein A agarose beads. For anti-FLAG IPs, anti-
FLAG antibody and Pierce protein G magnetic beads (ThermoFisher) were used. Following
extensive washing, bound protein was eluted by heating samples in Laemmli or NuPAGE sam-
ple buffer. Input lysates and IP samples were then processed for immunoblotting.
Immunoblotting
Cell lysates were combined with Laemmli or NuPAGE sample buffer, heated, and separated by
SDS-PAGE or Bolt Bis-Tris Plus PAGE (Thermo Fisher Scientific). Both methods were used
interchangeably for most proteins; for endogenous OASL, exclusively Bis-Tris PAGE was
used. Proteins were transferred to nitrocellulose or PVDF membranes using wet transfer and
either Towbin or NuPAGE transfer buffer, as appropriate. After blocking with 5% milk in
TBST, membranes were incubated with appropriate primary and secondary antibodies, devel-
oped using Lumi-Light (Roche Applied Science) or SuperSignal West Femto (Thermo Scien-
tific) chemoluminescence substrates, and signal was detected using either film exposure or an
Intas Chemidoc system.
Transduction
HFF, HuARLT2-rKSHV.219, or HuARLT2 were seeded in 6 well plates, then transduced with
1 ml filtered lentiviral-containing supernatant, 2 ml appropriate cell-specific medium, and
8 μg/ml polybrene. Plates were centrifuged at 690 × g for 90 min at 30˚C, incubated 1–3 h at
37˚C, then medium was exchanged. After 4 days, cells were seeded onto glass coverslips.
Immunofluorescence microscopy
HeLa cells were transfected in plastic multiwell plates and seeded onto glass coverslips approxi-
mately 24 h post transfection. For whole-cell staining, cells were fixed with 4% paraformalde-
hyde in PBS (PFA) approximately 48 h post transfection. For nuclear staining, 48 h post
transfection, HeLa cells were washed once with PBS, incubated 5 minutes in cold 1% NP-40
extraction buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40), washed once with
TBS, then fixed with 3% PFA [53]. HeLa cells and nuclei on coverslips were washed, blocked
and permeabilized with 5% FCS and 0.3% Triton-X 100 in PBS, then stained with the indicated
primary antibodies, followed by staining with Alexa Fluor 488 or Alexa Fluor 594 conjugated
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secondary antibodies. Antibodies were diluted in PBS containing 0.1% BSA and 0.3% Triton-X
100. Transiently transduced HFF, HuARLT2-rKSHV.219, and HuARLT2 cells were seeded
onto glass coverslips. For reactivation, cells were treated with 2μM sodium butyrate and 10%
SF-9 supernatant containing RTA-expressing baculovirus [29, 32]. Cells were fixed with 4%
PFA at various times post seeding, then processed essentially as for HeLa cells, with the addition
of Alexa Fluor 647 conjugated secondary antibodies. 293T or 293T OASL-/- cells were seeded
onto glass coverslips, then transfected with ORF20WT-myc with or without RIG-I N. Cells
were fixed with 4% PFA, permeabilized with 0.1% Triton X-100, blocked in PBS containing
10% FCS and 1% BSA, then stained with anti-myc and/or anti-IRF3 antibodies. HeLa S3 cells
were seeded onto glass coverslips. The following day, they were transfected with ORF20WT-
myc or OASL-V5 individually, or co-transfected with ORF20WT-myc and OASL-V5. 24 h post
transfection, HeLa S3 cells were fixed with methanol and PFA, blocked in PBS containing 10%
FCS and 1% BSA, then stained with primary and secondary antibodies diluted in PBS contain-
ing 1% BSA. All nuclei were counterstained with Hoechst. Images were obtained using a Nikon
ECLIPSE Ti-E inverted microscope equipped with a spinning disk device (Perkin Elmer Ultra-
view) and images were processed using Volocity (Improvision) and Adobe Photoshop.
Quantitative affinity purification coupled to mass spectrometry (q-AP-MS)
q-AP-MS to analyze protein-protein interactions was performed [54]. HeLa S3 cells were met-
abolically labeled for 10 days in lysine- and arginine-free DMEM (Pierce) supplemented with
dialyzed fetal bovine serum (Pierce), p/s (Invitrogen), 2 mM glutamine (Invitrogen), and either
0.22 mM 13C6
15N2 L-lysine-2HCl and 0.1385 mM
13C6 L-arginine-HCl (Pierce) for heavy-
labeled cells or the corresponding unlabeled amino acids (Pierce) for light-labeled cells. At day
10, approximately 7x106 heavy- or light-labeled HeLa S3 cells were plated into two 14 cm
dishes each. The following day, heavy and light HeLa S3 cells were transfected with 48.5 μg
DNA and 100 μl Lipofectamine 2000 (Life Technologies) diluted in arginine- and lysine-free
medium. For the forward experiment, heavy labeled HeLa S3 cells were transfected with
ORF20WT or OASL-myc, while light labeled HeLa S3 cells were transfected with LacZ-myc.
In the crossover experiment, the cell labels were inverted.
24–36 h post transfection, cells were carefully washed with ice-cold PBS and then lysed in 1
ml NP-40 lysis buffer (see recipe under Immunoprecipitations) containing 50U Emprove bio
benzonase (Merck #1.01695.0001) for 1 hour at 4˚C. Clarified supernatant was immunopre-
cipitated with 75 μl anti-c-myc microbeads (Miltenyi Biotec) for 1 h at 4˚C on a rotating plat-
form. Forward samples were combined or crossover samples were combined and then
immediately applied to equilibrated M columns in a μMACS separator (Miltenyi Biotec).
Beads were washed four times with 200 μl NP-40 lysis buffer, then twice with 200 μl Miltenyi
wash buffer 2. Bound proteins were eluted by 3 × 10 min incubations with 100 μl of 100 mM
glycine, pH 2.5; all fractions were combined. Eluted protein was precipitated by sequential
addition of 70 μl 2.5M sodium acetate, pH 5.0, 40 μl 20 mM Tris-HCl, pH 8.2, 1 μl Glycoblue
(Ambion), and 1600 μl 100% ethanol, followed by overnight incubation at 4˚C on a rocking
platform. Proteins were pelleted by centrifugation at 17,949 ×g for 60 min at 4˚C, the superna-
tant was removed, and the protein pellet was air dried at room temperature.
Later, the protein pellet was rehydrated, disulfide bonds were reduced and cysteines
blocked and alkylated, and an in-solution digest was performed using Lys-C and trypsin. Pep-
tides were further processed and analyzed by liquid chromatography coupled to tandem mass
spectrometry (LC-MS/MS) using a Dionex UltiMate 3000 n-RSLC low flow liquid LC system
(Thermo Scientific) connected to an LTQ Orbitrap VelosPro mass spectrometer (Thermo
Scientific).
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Peptides were identified using Proteome Discoverer 1.3.0.339 and a human protein data-
base extracted from SwissProt on a Mascot server (V 2.4, Matrix Science) with ORF20 and
LacZ manually added. The following search parameters were used: enzyme, trypsin; maximum
missed cleavages, 1; fixed modification, methyl methane thiosulfonate (C); variable modifica-
tion, oxidation (M); peptide tolerance, 5 ppm; MS/MS tolerance, 0.5 Da, Arg6 and Lys8 as var-
iable modifications for quantification. Peptide filter parameters were as follows: maximum
peptide rank of 1, peptide confidence of medium, and Mascot ion score of at least 25. The log2
fold change values of heavy/light values of each identified protein were calculated to facilitate
graphical visualization. Highly confident interaction partners were based on log2 fold change
values with an absolute value1 in one experiment and 0.7 in the other experiment. Highly
confident interaction partners for ORF20-myc and OASL-myc were entered into VennDis to
identify specific and shared proteins and to create a Venn diagram.
Sucrose gradient fractionation of ribosomes
293T cells were transfected with either ORF20WT, OASL-myc, or both combined. 24 h post
transfection, sucrose gradient fractionation of ribosomes was performed essentially as
described [55, 56]. Cell lysates (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1 mM DTT, 1% NP-
40 substitute, 100 μg/ml cycloheximide, DNase I, RNAse inhibitor, and protease inhibitor)
were prepared in the presence of 20 mM EDTA to disrupt ribosomes and polysomes or in the
presence of 10 mM MgCl2 to stabilize ribosomes and polysomes. Lysates were centrifuged
over a 5–45% linear sucrose gradient at 160,000 ×g in a Beckman SW40Ti rotor for 3 h at 4˚C.
Fractions were collected from the top using a Biocomp fractionator (Biocomp, NB Canada)
and absorbance at 254 nm was measured. RNA and total protein were extracted from 350 μl of
each fraction by using Trizol reagent (ThermoFisher Scientific) and subjected to denaturing
agarose gel electrophoresis or 10% SDS-PAGE and immunoblotting as appropriate.
Puromycin incorporation assay
293T cells were transfected with pcDNA4/myc-His B (EV), ORF20WT, ORF20FL, or
ORF20B, and a small amount of either pcDNA3.1(+) (EV, control) or RIG-I N to induce
expression of endogenous OASL. 24 h post transfection, newly synthesized proteins were
labeled with puromycin by treating cells for 15 minutes with 5 μg/ml puromycin [34]. Cells
were immediately lysed in 200 μl 1× NuPAGE LDS sample buffer supplemented with 3% beta-
mercaptoethanol, 250 U benzonase, and 5 mM MgCl2. Lysates were incubated for 30 minutes
at room temperature, denatured for 10 minutes at 70˚C, separated on 4–12% Bolt Bis-Tris plus
gradient gels (ThermoFisher Scientific) with NuPAGE MOPS SDS running buffer (50 mM
MOPS, 50 mM Tris base, 0.1% SDS, 1 mM EDTA), and transferred to 0.2 μm PVDF mem-
branes. Anti-puromycin, anti-OASL, anti-myc, and anti-actin immunoblotting were per-
formed sequentially. Between antibody incubations, membranes were treated with Restore
western blot stripping buffer (ThermoFisher) according to the manufacturer’s instructions.
Quantitative reverse transcriptase polymerase chain reaction
293 cells in 12-well plates or 293T cells in 6-well plates were transfected with the indicated plas-
mids for 24–48 h. For 293 cells, 24 h post transfection, cells were treated with Lipofectamine or
transfected with 5’pppRNA complexed with Lipofectamine for 24 h. RNA was prepared using
commercially available kits. cDNA was synthesized using anchored-oligo(dT)18 and the Tran-
scriptor first strand cDNA synthesis kit (Roche) or the iScript cDNA synthesis kit (Biorad). The
quantity of GAPDH, OASL, IRF3, IFNAR, STAT1, ORF20, ORF16, ORF46, or K8.1 cDNA was
determined using the LightCycler 480 Sybr Green I Master 2× mix (Roche), 125 nM of gene-
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specific forward and reverse oligonucleotides, and 1 μl cDNA, or the GoTaq 2x qPCR master mix,
200 nM of gene-specific forward and reverse oligonucleotides, and 1 μl cDNA, in a Roche Light-
Cycler 480 instrument. mRNA levels were quantified relative to GAPDH and the 2-ΔΔCT method
[57] was used to compare the amount of the indicated mRNA between samples. The forward and
reverse oligonucleotide sequences were GAAGGTGAAGGTCGGAGTC and GAAGATGGTGA
TGGGATTTC for GAPDH, GCCATGTACTCCAGAACTCATC and GGCCTGGGATAACTC
ATTGTAA for OASL, AGCCTCGAGTTTGAGAGCTA and TGGTCCGGCCTACGATG for
IRF3, CACCATTTCGCAAAGCTCAG and ACCATCCAAAGCCCACATAA for IFNAR, GCT
GCAGAACTGGTTCACTAT and GGGTCATGTTCGTAGGTGTATTT for STAT1, CGATCT
ATGGCGGTTTCTAAGT and TTACGCAGTCGGCAATTCT for ORF20, AGATTTCACAGC
ACCACCGGTA and CCCCAGTTCATGTTTCCATCGC for ORF16, CACTGCTGCGATCCA
GAGGATA and GAACCTGACATTGCGGATCCAC for ORF46, and TAAACGGGACCAGAC
TAGCAGC and GTTTTCTGCGACCGGTGATACG for K8.1. The oligonucleotide sequences
for ORF16, ORF46, and K8.1 were previously published [58].
siRNA knockdown of IRF3, STAT1, or IFNAR1
All siRNAs were purchased from Dharmacon/GE Life Sciences: ON-TARGETplus non-targeting
pool (D-001810-10-20, control siRNA), ON-TARGETplus human IRF3 SMARTpool siRNA (L-
006875-00-0010), ON-TARGETplus human STAT1 SMARTpool siRNA (L-003543-00-0005),
and ON-TARGETplus human IFNAR1 SMARTpool siRNA (L-020209-00-0005). 293T cells were
reverse transfected with siRNAs complexed with Lipofectamine 2000. Per well of a 6 well plate,
1 μl of 50μM siRNA stock was combined with 199 μl OptiMEM. Separately, 6 μl Lipofectamine
2000 was combined with 194 μl OptiMEM. Diluted Lipofectamine was added to diluted siRNA,
then all 400 μl were added directly to the plate. 293T cells (450,000–600,000 cells) were resus-
pended in 1.6 ml/well, then added to the siRNA-Lipofectamine complexes. 2 days later cells were
co-transfected with pcDNA4/myc-His B (EV) or ORF20WT, and either pcDNA3.1(+) (EV) or
RIG-I N. 24 h later, RNA was prepared and q-RT-PCR was performed for OASL, GAPDH, and
either IRF3, STAT1, or IFNAR as appropriate. In parallel, 293T cells were transfected with siRNAs
for preparation of protein lysates and immunoblotting analysis.
OASL reconstitution and infection assays
150,000 293T OASL-/- cells were seeded per well in 24-well plates. The following day, replicate
wells were transfected with either pcDNA3.1(+) (EV), mOASL1, or hOASL: 40μl of DNA
mixes containing 748 ng DNA and 2.62μl Fugene HD in OptiMEM were added per well.
Approximately 24 hours after transfection, one master dilution of the appropriate virus was
prepared, then used to infect transfected cells with VSV-GFP for 1 hour, MHV68-GFP for 2
hours, or with KSHVLYT wildtype or KSHVLYT ORF20stop for 4 hours, at 37˚C. Virus inocu-
lum was removed, cells were washed once with medium, and fresh medium was added. The
next day, 16 h, 20 h, or 24 h post infection for VSV-GFP, MHV68-GFP, or KSHVLYT, respec-
tively, cells were detached using trypsin, fixed for 30 minutes with 4% PFA, and the number of
green cells was determined by flow cytometry on an LSRII instrument. For growth curves with
MHV68-GFP, at the indicated time points 10% of medium was harvested, frozen at -70˚C, and
replaced with fresh medium. After all samples were collected, the titers in supernatants were
determined by TCID50 assay on M2-10B4 cells.
Reactivation of HuARLT2-rKSHV.219 cells
1 day after seeding in Cellovations endothelial cell medium lacking selection antibiotics,
HuARLT2-rKSHV.219 cells were reactivated by the addition of 2 μM sodium butyrate and
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10% SF-9 supernatant containing KSHV RTA-expressing baculovirus, kindly provided by
Thomas F. Schulz [29, 32]. Cells were incubated for various times, then fixed for immunofluo-
rescence or lysed for preparation of RNA.
Statistical analysis
Statistical analysis was performed using Graphpad Prism. Statistical significance was deter-
mined by 1way ANOVA followed by Tukey’s multiple comparison test (Fig 9B–9D, Fig 11, S6
Fig), 1way ANOVA followed by Dunnett’s multiple comparison test (Fig 10E), or by two-tailed
unpaired t test (Fig 10B–10D, 10F and 10H). For all figures, ns indicates not significant,  indi-
cates P<0.05,  indicates P<0.01, and  indicates P<0.001.
Supporting information
S1 Fig. Subcellular localization of ORF20 and OASL is cell-type independent. (A+B) HFF-1
(A) or HuARLT2 (B) were transiently transduced with lentiviruses encoding the indicated
construct. Transduced cells were seeded onto coverslips, then processed for anti-myc (pink)
immunofluorescence. (C) 293T or 293T OASL-/- were transiently transfected with ORF20WT-
myc, then processed for anti-myc (pink) immunofluorescence. (D) 293T cells were transiently
transfected with EV or ORF20WT-myc and RIG-I N, then processed for anti-myc (pink) and
anti-endogenous IRF3 (green) immunofluorescence. (A-D) Nuclei were counterstained with
Hoechst. Scale bar = 10 μm
(TIF)
S2 Fig. OASL-V5 co-immunoprecipitates with ORF20-myc-GFP but not nucleolar
GFP-NS1A. (A, B) 293T cells were transfected with EV, two separate clones of ORF20-myc-
GFP, RIG-I GFP, GFP-NS1A, and OASL-V5 or EV as indicated. (A) An anti-V5 immunopre-
cipitation of RIPA lysates was performed and input lysates and immunoprecipitates were
immunoblotted with anti-GFP and anti-V5 antibodies. (B) An anti-GFP immunoprecipitation
of RIPA lysates was performed and input lysates and immunoprecipitates were immuno-
blotted with anti-V5 and anti-GFP antibodies as indicated.
(TIF)
S3 Fig. Amino acid sequence alignment of selected UL24 family members. The amino acid
sequences of HSV-1 UL24, HCMV UL76, MCMV M76, KSHV ORF20WT (FL with genomic
ORF20A and ORF20B start codons), KSHV ORF20A, KSHV ORF20B, and MHV68 ORF20
were aligned using Clustal W2.
(TIF)
S4 Fig. OASL and most mutants localize to the cytoplasm and nucleoli of transfected cells.
HeLa cells were transfected with the indicated plasmid and processed for whole cell and
nuclear anti-V5 (green) and anti-fibrillarin (red) immunofluorescence. Nuclei were counter-
stained with Hoechst (blue). Images are representative of three independent experiments.
Scale bar = 20 μm.
(TIF)
S5 Fig. ORF20B mutants localize to the nuclei and nucleoli of transfected cells. HeLa cells
were transfected with plasmids expressing the indicated myc-tagged ORF20B deletion mutant
plasmid and processed for whole cell and nuclear anti-myc (green) and anti-fibrillarin (red)
immunofluorescence. Nuclei were counterstained with Hoechst (blue). Images are representa-
tive of three independent experiments. Scale bar = 30 μm (whole cell IF) and 15 μm (nuclear IF)
(TIF)
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S6 Fig. Additional nuclear KSHV ORFs do not upregulate OASL induction and verifica-
tion of siRNA knockdown. (A) 293T cells were co-transfected with the indicated plasmids for
24 h. The amount of OASL mRNA was determined by q-RT-PCR. (B, C, D) IRF3, IFNAR, or
STAT1 mRNA levels were measured in the same samples described in Fig 9D. (A-D) Data
shown are means + SD of duplicates from at least two experiments. Statistical significance was
measured by one-way ANOVA followed by Tukey’s posttest  P<0.01,  P<0.001 (B, D) In
parallel with preparation of samples for qPCR, protein lysates were prepared and analyzed for
(B) IRF3 or (D) STAT1 expression by immunoblotting.
(TIF)
S7 Fig. ORF20 does not affect the interaction between OASL and RIG-I or their co-locali-
zation. (A) 293T cells were transfected with the indicted combinations of FLAG-RIG-I,
OASL-V5, ORF20WT-myc, and/or EV. NP40 lysates were subjected to anti-FLAG IP. Input
lysates and immunoprecipitates were subjected to anti-FLAG, anti-V5, and anti-myc immuno-
blotting. (B and C) HeLa S3 cells on glass coverslips were transfected with the indicated plas-
mids, then processed for anti-FLAG, -V5, or -myc immunofluorescence as appropriate. Nuclei
were counterstained with Hoechst. Scale bar = 20 μm.
(TIF)
S1 Dataset. ORF20 interactome. Interacting partners of ORF20 were identified by q-AP-MS
and data were analyzed using Proteome Discoverer. The data as exported from Proteome Dis-
coverer, as well as annotated results, are provided.
(XLSX)
S2 Dataset. OASL interactome. Interacting partners of OASL were identified by q-AP-MS
and data were analyzed using Proteome Discoverer. The data as exported from Proteome Dis-
coverer, as well as annotated results, are provided.
(XLSX)
S1 Supporting Information. Highly confident interaction partners for ORF20 and OASL
identified by q-AP-MS and comparison of specific and shared partners. This file shows the
highly confident interaction partners for ORF20 and OASL identified by q-AP-MS (tabs: ORF20-
myc partners and OASL-myc partners), taking into account the log2 fold change values and the
H/L counts. A protein was characterized as highly confident if the log2 fold change had an absolute
value1 in one experiment and0.7 in the other experiment. The transfected proteins (ORF20,
OASL, and LacZ) were omitted, as were less confident interacting partners. The highly confident
interaction partners were entered into VennDis to create a Venn Diagram. The proteins identified
by VennDis as ORF20-specific, shared, and OASL-specific are listed (tab: specific and shared).
(XLSX)
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